| Trial ID: | L1728 |
| Source ID: | NCT06720233
|
| Associated Drug: |
Sal-0951 Tablets
|
| Title: |
Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Anemia
|
| Interventions: |
DRUG: SAL-0951 tablets
|
| Outcome Measures: |
Primary: Mean Hb level and 95% CI during the evaluation period after the 24-week treatment period or at the end of treatment, (Hb levels during the evaluation period are defined as the mean value of Hb levels at Weeks 20, 22, and 24 \[or end-of-treatment date\]), at Weeks 20, 22, and 24 [or end-of-treatment date] |
|
| Sponsor/Collaborators: |
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
37
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-02-22
|
| Completion Date: |
2024-10-28
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-06
|
| Locations: |
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510062, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06720233
|
